Upadacitinib
VIDEO: Studies show no increased risk of cancer, CV events with JAK inhibitors
In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.
FDA approves Rinvoq for JIA, psoriatic arthritis in children aged 2 years and older
The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.
Evolving insights on JAK inhibitors for rheumatoid arthritis management
Physician understanding about the safety and efficacy of Janus kinase inhibitors for patients with rheumatoid arthritis has evolved with real-world and clinical trial data.
Nearly half of patients with giant cell arteritis achieve remission with upadacitinib
Nearly half of patients with giant cell arteritis who received upadacitinib while tapering steroids achieved remission from weeks 12 through 52 in a phase 3 trial, according to a press release from AbbVie.
Patients with atopic dermatitis report year-long improvements with upadacitinib
Adults and adolescents with moderate to severe atopic dermatitis treated with upadacitinib reported year-long improvements in skin symptoms, mental health and quality of life, according to a study.
‘Efficacy will lead’ as first-line JAK inhibitor use picks up in moderate to severe UC
Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results.
Rinvoq 45 mg prompts ‘rapid resolution’ of Crohn’s disease symptoms as early as day 5
Once-daily Rinvoq 45 mg provided “rapid relief” of stool frequency and abdominal pain score within the first week of induction therapy in patients with moderately to severely active Crohn’s disease, according to a data analysis.
Q&A: Rheumatologists encouraged to address gender disparities in RA
Although it is still unclear why gender differences exist in rheumatoid arthritis, it is known that the disease is more prevalent among and tends to be more painful for women.
Upadacitinib improves vitiligo among patients without reaching plateau for 1 year
SAN DIEGO — Patients with nonsegmental vitiligo continually improved with upadacitinib treatment up to 1 year, according to a speaker at the American Academy of Dermatology Annual Meeting.
VIDEO: Multimodal care, ‘aggressive’ medical treatment a must for perianal Crohn’s disease
In this Healio video exclusive, Miguel Regueiro, MD, shares highlights from his presentation at the GUILD Conference, where he discussed the importance of early, multimodal intervention in perianal fistulizing Crohn’s disease.